PMID- 31163679
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20201001
IS  - 2072-6694 (Print)
IS  - 2072-6694 (Electronic)
IS  - 2072-6694 (Linking)
VI  - 11
IP  - 6
DP  - 2019 Jun 3
TI  - Natural Killer Cells as Allogeneic Effectors in Adoptive Cancer Immunotherapy.
LID - 10.3390/cancers11060769 [doi]
LID - 769
AB  - Natural killer (NK) cells are attractive within adoptive transfer settings in 
      cancer immunotherapy due to their potential for allogeneic use; their 
      alloreactivity is enhanced under conditions of killer immunoglobulin-like 
      receptor (KIR) mismatch with human leukocyte antigen (HLA) ligands on cancer 
      cells. In addition to this, NK cells are platforms for genetic modification, and 
      proliferate in vivo for a shorter time relative to T cells, limiting off-target 
      activation. Current clinical studies have demonstrated the safety and efficacy of 
      allogeneic NK cell adoptive transfer therapies as a means for treatment of 
      hematologic malignancies and, to a lesser extent, solid tumors. However, 
      challenges associated with sourcing allogeneic NK cells have given rise to 
      controversy over the contribution of NK cells to graft-versus-host disease 
      (GvHD). Specifically, blood-derived NK cell infusions contain contaminating T 
      cells, whose activation with NK-stimulating cytokines has been known to lead to 
      heightened release of proinflammatory cytokines and trigger the onset of GvHD in 
      vivo. NK cells sourced from cell lines and stem cells lack contaminating T cells, 
      but can also lack many phenotypic characteristics of mature NK cells. Here, we 
      discuss the available published evidence for the varying roles of NK cells in 
      GvHD and, more broadly, their use in allogeneic adoptive transfer settings to 
      treat various cancers.
FAU - Lupo, Kyle B
AU  - Lupo KB
AD  - Department of Industrial and Physical Pharmacy, Purdue University, West 
      Lafayette, IN 47907, USA. klupoo@purdue.edu.
FAU - Matosevic, Sandro
AU  - Matosevic S
AUID- ORCID: 0000-0001-5118-2455
AD  - Department of Industrial and Physical Pharmacy, Purdue University, West 
      Lafayette, IN 47907, USA. sandro@purdue.edu.
AD  - Purdue Center for Cancer Research, West Lafayette, IN 47907, USA. 
      sandro@purdue.edu.
LA  - eng
GR  - UL1TR001108/Indiana Clinical and Translational Sciences Institute/
PT  - Journal Article
PT  - Review
DEP - 20190603
PL  - Switzerland
TA  - Cancers (Basel)
JT  - Cancers
JID - 101526829
PMC - PMC6628161
OTO - NOTNLM
OT  - HLA mismatch
OT  - allogeneic immunotherapy
OT  - graft-versus-host disease
OT  - natural killer cells
COIS- The authors declare no conflicts of interest.
EDAT- 2019/06/06 06:00
MHDA- 2019/06/06 06:01
PMCR- 2019/06/03
CRDT- 2019/06/06 06:00
PHST- 2019/05/09 00:00 [received]
PHST- 2019/05/25 00:00 [revised]
PHST- 2019/05/30 00:00 [accepted]
PHST- 2019/06/06 06:00 [entrez]
PHST- 2019/06/06 06:00 [pubmed]
PHST- 2019/06/06 06:01 [medline]
PHST- 2019/06/03 00:00 [pmc-release]
AID - cancers11060769 [pii]
AID - cancers-11-00769 [pii]
AID - 10.3390/cancers11060769 [doi]
PST - epublish
SO  - Cancers (Basel). 2019 Jun 3;11(6):769. doi: 10.3390/cancers11060769.